Index

Numbers in italics refer to figures; numbers in bold refer to tables.

Acceptance and Commitment Therapy (ACT) 76
acupuncture 22, 99–100, 102
acupuncture-like Transcutaneous Electrical Nerve Stimulation (AL-TENS) 92, 93, 94
adjuvant analgesics 25, 35, 48, 49, 50
allodynia 5, 93
alternative therapies 99–102
amethocaine 62
amitriptyline 35, 40, 41, 45, 46, 68
analgesic ladder 34, 48
Anterior Cingulate Nucleus (ACN) 33–4
anticonvulsants 27–8
antidepressants 27, 28–9
See also tricyclic antidepressants (TCAs)
anti-epileptic drugs 72
anti-inflammatory drugs 71
non-steroidal (NSAIDs) 62, 63, 68
anxiety 14
appraisal-based models 75
aromatherapy 101–2
arthritis 18–19
rheumatoid 17, 19, 63, 97
assessment 79
children 60–1
coping 15
emotional distress 14
expressions of pain 14
functioning 14–15
interviews 12–14
medical and physical evaluations 11
pain intensity 14
pain quality 14
screening questions 12
secondary gain 15
self-report instruments 14
asthma 62
baclofen 83
Beck Depression Inventory (BDI) 14
behaviour modification 89–90
benzodiazepines 41, 54
bone metastases 49, 57
bone pain 50, 52–3
botulinum toxin A 29
British Association for the Study of Headache (BASH) 45
British National Formulary 61
Children 61
bupivacaine 81, 83
buprenorphine 58–9, 105, 106, 107
cancer-induced bone pain (CIBP) 50–1
cancer pain 48–53
assessment 49–50
children 63
intrathecal drug delivery 83
management 49–52
new treatments 53
opioid responsiveness 50–2
special considerations 52–3
treatment-related 49
 cannabinoids 29, 53
capsaicin 29, 53, 68
carbamazepine 28, 40, 41, 46, 107
cardiac pacemakers 93
catastrophising 75
central sensitisation 7–9, 32, 38
central sensitivity syndrome (CSS) 23
children 60–4
analgesia 61–2
assessment 60–1
cancer pain 63
chronic pain 63–4
post-operative pain 62–3
procedural pain 62
chronic pain associated problems 73
biopsychosocial model 11, 22
cost 4
definition 1
epidemiology 1–3
impact 3
inflammatory 5
mechanisms 5–10
neuropathic 5
risk factors 3, 76–7
widespread 47, 67, 68
See also assessment; pain; psychological aspects
ciprofloxacin 107
clonidine 83
cold therapy 86–7
COMFORT pain scale 60, 61
Common Sense Self-Regulatory Model 75
complementary therapies 99–102
Complex Regional Pain Syndrome (CRPS) 64
computed tomography (CT) 44, 50
coping 15
corticosteroids 79
C-reactive protein (CRP) 55
cyclobenzaprine 68
cysteine 450 isoenzymes 62, 106–7
dementia 66
depression 3, 14, 90
deprivation 3
diazepam 46
diclofenac 62
disability 66
109
doulepin 47

drug addiction 54, 56

see also drug dependence; substance dependence

drug dependence 54–9

acute pain treatment 54–5

chronic pain treatment 55–9

maintenance treatment 58–9

palliative care 55

screening 56–8

drug tolerance 56

DSM IV, substance abuse and dependence criteria 54, 55

dysmenorrhoea 31, 32

dementia 73

etopic pregnancy 70

educational interventions 90

electrotherapies 87–8

EMLA 62

emotional distress 14

epidurals 29–30, 81–2

epilepsy 93

essential oils 101–2

exercise therapy 89

Faces Pain Scale-Revised 60, 61

facet joint injection 81

Fear–Avoidance Model 74

fentanyl 58, 105, 106

fibroids 71

fibromyalgia 19, 67, 68

FLACC pain scale 60, 61

fluoxetine 47, 106

foetal anticonvulsant syndrome 72

functional magnetic resonance imaging (fMRI) 33

GABA 9

gabapentin 28, 35, 40, 41, 50, 68

glutamate receptors 8, 9

haloperidol 41, 107

headache 42–7

classification 42, 43

cluster 43–6

examination 43–4

history 42–3, 44

investigations 44

management 44–5

medication overuse 46

prevalence 42

primary 44, 45–6

secondary 44

tension-type 45

heterotrophic pregnancy 70

hydromorphone 105, 106

hydrocephalus 71

hyperalgesia 5, 32, 48–9

hypnosis 100–1, 102

hypernogusium 108

ibuprofen 46, 62

ice therapy 86–7

identity 75–6

immobilisation 89

see also movement restriction

immune cells 9

infants 60, 61–2

inflammatory pain 5, 71–2

injections 22

facet joint 81

myofascial trigger point 80–1

selective nerve root 82–3

interferential therapy (IF) 88

interleukin-6 (I-L6) 53

International Association for the Study of Pain (IASAP) 1

interventional procedures 79–84

interviews 12–14

intrathecal drug delivery 83, 84

irritable bowel syndrome (IBS) 19, 23, 31, 33–4, 39, 47

joint mobilisation 88

ketamine 29, 35, 41, 68

knee pain 17, 18, 97, 100

Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) 26

lidocaine 29, 41, 62, 68

local anaesthesia 40, 62, 63, 79

low back pain 20–4

central sensitivity syndrome 23

development 21, 22

guidelines 20

magnetic resonance imaging (MRI) 21

mechanical 20, 21

older adults 67

pregnancy 70

prevalence 20

psychological issues 22–3

risk factors 22, 23

Transcutaneous Electrical Nerve Stimulation (TENS) 97

treatment 21–2

low level laser therapy (LLLT) 87

lumbar sympathetic block 83

magnetic resonance angiography (MRA) 44

magnetic resonance imaging (MRI) 21, 44, 67, 71, 82

manipulations 22, 88

manual therapies 88–9

McGill Pain Questionnaire (MPQ) 14

medication overuse headache (MOH) 46

metastatic cancer 53

methadone 38, 51, 58–9, 105, 106, 107

microglia 9

microvascular decompression 46

migraine 45

miscarriage 71, 70

mobilisations 88

mood problems 17, 74, 75, 76

morphine 53, 71–2, 105, 106, 107

movement restriction 86, 89

Moxduo 53

Multidimensional Pain Inventory (MPI) 14

musculoskeletal pain 16–19

anatomy and physiology 16–17

associated problems 17

classification 17

pregnancy 69–70

regional 17–18

Transcutaneous Electrical Nerve Stimulation (TENS) 97

myocardial ischaemia 31

myofascial pain 67

myofascial trigger point injection 80–1

naltrexone 34, 36, 53

National Institute for Health and Clinical Excellence (NICE) guidelines low back pain 21, 22

osteoarthritis 18–19

spinal cord stimulation 29

Transcutaneous Electrical Nerve Stimulation (TENS) 97

neck pain 81, 89, 97, 100

neonatal abstinence syndrome 71

neonates 61–2

nerve root blocks 29–30, 82–3

neuropathic pain 5, 25–30

artiology 26

cancer-related 50

characteristics 27

children 63–4

diagnosis 26–7

intrathecal drug delivery 83

management 27–30
mechanisms 25–6
older adults 67, 68
post surgical 25, 38–9
pregnancy 25
prevalence 25
screening tools 26
nociceptive pain 71–2, 67, 68
older adults 67, 68
post surgical 25, 38–9
pregnancy 72
prevalence 25
screening tools 26
nociceptive pain 71–2, 67, 68
non-steroidal anti-inflammatory drugs (NSAIDs) 62, 64, 68
nortryptiline 47
numerical scale (NRS) 14
older adults 32, 65–8
pain co-morbidities 67, 68
pain contributors 67
‘pain signature’ 67
risk of disability 66
treatment expectations 65–6
treatment plan 67–8
treatment targets 66
opioid agreements/contracts 58, 105
opioid maintenance 58–9
opioid receptors 103–4
opioid responsiveness 50–2
Opioid Risk Tool (ORT) 57
opioids
adverse effects 107–9
cancer pain 48–52
children 62–3
developed tolerance 38
drug interactions 106–7
intra-thecal delivery 83
neuropathic pain 29
older adults 68
pharmacokinetic aspects 106–7
pharmacology 105–6
pregnancy 71–2
principles of ‘universal precautions’ 56, 57
risks 57, 104–5
toxicity 48–9
urine testing 58
visceral pain 34, 38
see also drug dependence
oral/facial pain 42–7
osteoarthritis 17, 18–19, 97, 100
ovaries 71
oxcarbazepine 46
oxycodone 40, 53, 58, 105, 106, 107
oxygen treatment 46
pain
definition 1
expressions 14
intensity 14
pathways 5–6
quality 14
spontaneous 5, 6
see also chronic pain
pain-related beliefs 74, 76–7, 90
palliative care 55, 56
Pancoast’s tumour 49, 50
paracetamol 62, 63, 71
paracetamol 106
pelvic belt 70
pelvic pain 32, 35, 70
peripheral sensitisation 6–7, 8, 32, 38
persistent idiopathic facial pain 46–7
phantom limb pain 29, 63–4, 83
physiotherapy 86–90
electrotherapy 87–8
manual therapies 88–9
positron emission tomography (PET) 33
post-surgical pain 3, 37–41
aetiology 37–9
assessment 37
children 62–3
incidence 39
management 40
neuropathic pain 25
risk factors 39
pain 41
pregabalin 28, 40, 41, 68
pregnancy 69–72
acute abdomen 71
aromatherapy 102
chronic pain 71–2
ectopic 70
gestational problems 70
heterotropic 70
medication 71–2
musculoskeletal problems 69–70
physiological changes 69
renal tract 71
reproductive organs 71
transcutaneous electrical nerve stimulation (TENS) 70, 93, 95
pelvic–lidocaine mixture (EMLA) 62
psychological aspects 22–23, 73–7
radio frequency neurotomy 79, 81
rheumatoid arthritis 17, 19, 63, 97
rifampicin 107
Sativex 53
Screen and Opioid Assessment for Patients with Pain (SOAPP) 57
screening questions 12
secondary gain 15
selective nerve root injection 82–3
selective serotonin reuptake inhibitors (SSRIs) 29, 47, 72, 106
self-report assessment instruments 14, 26, 27, 38, 60–1
self-report Leeds Assessment of Neuropathic Symptoms and Signs (s-LANSS) 26, 37, 38
sensory neurons 5–6
serotonin noradrenaline reuptake inhibitors (SNRIs) 27, 29
Short-Form McGill Pain Questionnaire (SF-MPQ) 14
sodium channel blocking agents 6, 35
spinal adjustments 86–90
spinal cord compression 49, 51
spinal cord neurons 7, 9
spinal cord stimulation (SCS) 29, 83–4
spontaneous pain 5, 6, 8
stabilisation splint therapy 46
steroids 18, 79, 81–2
see also corticosteroids
substance abuse 55
substance dependence 54, 55, 56
see also drug dependence
symptom diaries 45
tapentadol 53, 105–6
targinact 53
temperomandibular disorders (TMD) 44, 46–7
tender spots 19
tension-type headache 45
thrombosis 71
tonsillectomy 62, 63
topical agents 29
tramadol 29, 40, 105, 106
transcutaneous electrical nerve stimulation (TENS) 87–88, 91–7
acupuncture-like (AL-TENS) 92, 93, 94
acute pain 96–7
adverse events 95
cancer pain 52
chronic pain 97
clinical research evidence 95–7
contradictions and precautions 93–5
conventional 92, 93, 94
electrode positions 93, 95
intense 92, 95
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcutaneous Electrical Nerve Stimulation (TENS) (continued)</td>
</tr>
<tr>
<td>pregnancy 70, 93, 95</td>
</tr>
<tr>
<td>techniques and mechanism 91–2</td>
</tr>
<tr>
<td>tricyclic antidepressants (TCAs) 28–9, 35, 41, 68, 72</td>
</tr>
<tr>
<td>trigeminal neuralgia 46, 47</td>
</tr>
<tr>
<td>triggering factors 45</td>
</tr>
<tr>
<td>trigger points 80</td>
</tr>
<tr>
<td>triptans 45, 46</td>
</tr>
<tr>
<td>ultrasound 88</td>
</tr>
<tr>
<td>ureteric colic 32</td>
</tr>
<tr>
<td>uterus 70, 71</td>
</tr>
<tr>
<td>verapamil 45–6</td>
</tr>
<tr>
<td>verbal ratings scale (VRS) 14</td>
</tr>
<tr>
<td>visceral pain 31–6</td>
</tr>
<tr>
<td>assessment 32–4</td>
</tr>
<tr>
<td>characteristics 32</td>
</tr>
<tr>
<td>management 34–6</td>
</tr>
<tr>
<td>pathophysiology 31–2</td>
</tr>
<tr>
<td>pregnancy 71</td>
</tr>
<tr>
<td>visual analogous scale (VAS) 14</td>
</tr>
<tr>
<td>visualisation 101</td>
</tr>
</tbody>
</table>